相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The risk of hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study
Daphine Namara et al.
Lancet Global Health (2022)
Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
Workagegnehu Hailu et al.
INTERNATIONAL MEDICAL CASE REPORTS JOURNAL (2021)
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy
Shahini Shah et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2021)
Dolutegravir-associated hyperglycaemia in patients with HIV
Mohammed Lamorde et al.
LANCET HIV (2020)
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
Willem D F Venter et al.
Lancet HIV (2020)
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1
A. Ayouba et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care
Peter F Rebeiro et al.
Open Forum Infectious Diseases (2019)
341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States
Ricky Hsu et al.
Open Forum Infectious Diseases (2019)
Dolutegravir-induced hyperglycaemia in a patient living with HIV
Milena McLaughlin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
Josep M. Llibre et al.
LANCET (2018)
Integrase strand transfer inhibitor-associated diabetes mellitus: A case report
Peter S. Fong et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2017)
Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial
Sharon Walmsley et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2015)
Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
Antonella Castagna et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet et al.
LANCET (2014)
Can early therapy reduce inflammation?
Netanya G. Sandler et al.
CURRENT OPINION IN HIV AND AIDS (2014)
The global status of resistance to antiretroviral drugs
S Vella et al.
CLINICAL INFECTIOUS DISEASES (2005)
分享论文
